RNA-Based Therapeutics and Vaccines Market, By Product Type (RNA Therapeutics and RNA Vaccines), By RNA Technology, By Indication, By End User, By Country, and By Region Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
|
Report ID
AV4672
|
Published Date
January 2026
|
Pages
356
|
Industry
Healthcare
|
|
|
Base Year
2025
|
Historical Data
2019-2024
|
Delivery Timeline
24 Hour
|
REPORT HIGHLIGHT
RNA-Based Therapeutics and Vaccines Market size was valued at US$ 1,285.10 Million in 2024, expanding at a CAGR of 5.50% from 2025 to 2032.
The RNA-Based Therapeutics and Vaccines market has emerged as a critical segment in biopharmaceutical research due to its ability to enable faster and more flexible drug development compared with traditional approaches. RNA platforms function by delivering genetic instructions to produce therapeutic proteins, inhibit harmful protein production, or modulate gene expression. The global success of mRNA vaccines validated the technology at scale, significantly boosting confidence in RNA as a versatile platform for a wide range of therapies. Since then, development has expanded beyond infectious diseases into oncology, rare genetic disorders, and other chronic conditions, positioning RNA therapeutics as a key component across multiple therapeutic areas and pipeline strategies.
Market growth is closely linked to advancements in delivery technologies and manufacturing capabilities. Efficient delivery systems, such as lipid nanoparticles and other novel formulations, are critical to ensuring that RNA therapeutics reach the target tissue, maintain safety, and achieve clinically viable dosing schedules. Simultaneously, scaling production to commercial volumes requires specialized raw materials and expertise, including nucleotides, enzymes, capping reagents, ionizable lipids, plasmid DNA, and advanced analytical testing. These operational factors directly impact development timelines, cost of goods, and the transition from early-stage clinical trials to full-scale commercialization, making manufacturing strategy an integral part of RNA R&D planning.
RNA-Based Therapeutics and Vaccines Market- Market Dynamics
Government Immunization Programs and Preparedness Spending Driving Steady Demand for RNA Platforms
Government-backed vaccination programs and pandemic preparedness funding have been key drivers for the RNA-Based Therapeutics and Vaccines market since 2020, as they generate substantial real-world demand and lower commercialization risk for RNA platforms. Mass vaccination campaigns provide the clearest example: according to the U.S. Centers for Disease Control and Prevention (CDC), more than 600 million COVID19 vaccine doses were administered in the United States by 2023–2024, demonstrating the feasibility of large-scale, sustained deployment through boosters and ongoing protection programs. Public funding has also accelerated RNA manufacturing and supply chain capacity. For instance, the U.S. Department of Health and Human Services (HHS) reported that Operation Warp Speed and related federal initiatives in 2020–2021 invested several billion dollars in a combination of R&D support and advance purchase agreements, enabling expansion of GMP production facilities and securing critical inputs such as lipids, enzymes, and fill-finish capabilities. Globally, demand for vaccines has remained structurally high beyond the acute pandemic phase. The World Health Organization (WHO) noted that while routine immunization coverage fell in 2020–2021, it began recovering in 2022–2023, leaving catch-up vaccination needs in multiple countries and reinforcing the importance of scalable RNA platforms. Together, these government and public health initiatives continue to support investment in RNA
RNA-Based Therapeutics and Vaccines Market- Segmentation Analysis:
RNA vaccines have demonstrated strong, large-scale demand since 2020, sustaining high investment interest across the RNA therapeutics and vaccines market. Deployment volumes provide a clear signal of market need: according to the U.S. Centers for Disease Control and Prevention (CDC), the United States administered hundreds of millions of COVID19 vaccine doses cumulatively, with ongoing booster and seasonal dosing tracked through 2024 via the CDC COVID Data Tracker. Regulatory activity has further reinforced platform viability, with the U.S. Food and Drug Administration (FDA) authorizing and approving updated COVID19 vaccine formulations aligned with circulating variants from 2020 to 2023, demonstrating that RNA vaccine programs can operate on a repeat-update model rather than a one-time rollout.
Public funding and preparedness programs have strengthened the business case for manufacturing scale-up. According to the U.S. Department of Health and Human Services (HHS), federal COVID19 response initiatives in 2020–2021 included multibilliondollar awards and advance purchase agreements to accelerate vaccine development and expand production capacity, ensuring broader supply chain readiness for advanced modalities.
mRNA technology gained significant platform validation during 2020–2024 by transitioning from clinical trials to global manufacturing networks and formal capacity-building programs. Government investments have helped reduce manufacturing bottlenecks and improve regional readiness. For example, the Government of Canada’s Biomanufacturing and Life Sciences Strategy, initiated in 2021, allocated billions of Canadian dollars to expand domestic biomanufacturing capacity, including capabilities for mRNA vaccines. Globally, the World Health Organization (WHO) reported that mRNA technology transfer and training initiatives continued through 2023–2024 to enhance skills and production capacity across multiple regions.
RNA-Based Therapeutics and Vaccines Market- Geographical Insights
From 2020 to 2024, RNA commercialization and scale-up efforts were heavily concentrated in North America and Europe, driven by the combination of substantial public-sector purchasing, established biologics manufacturing infrastructure, and strong clinical development capabilities. Demand is evident in vaccination volumes: according to the U.S. Centers for Disease Control and Prevention (CDC), the United States administered hundreds of millions of COVID19 vaccine doses cumulatively, with ongoing reporting through 2024 (CDC COVID Data Tracker). This sustained demand required extensive fill-finish capacity, cold-chain logistics, and lot release testing.
Public-sector funding further reinforced supply expansion and long-term preparedness. The U.S. Department of Health and Human Services (HHS) reported that federal COVID19 response initiatives during 2020–2021 included multibilliondollar awards and advance purchase agreements, which accelerated vaccine development and expanded manufacturing capacity, thereby strengthening RNA supply chains.
Beyond the U.S. and European core markets, building regional capability remained a key focus. The World Health Organization (WHO) documented ongoing mRNA technology transfer and training initiatives through 2023–2024, aimed at expanding local manufacturing expertise and reducing dependence on a limited number of production hubs. These coordinated efforts underscore how government support, infrastructure readiness, and training programs collectively enabled rapid RNA scale-up while laying the groundwork for future global production resilience.
United States RNA-Based Therapeutics and Vaccines Market- Country Insights
The United States remains the leading single-country market for RNA-based products due to its large-scale deployment volumes, abundant capital resources, and an established regulatory framework that supports formulation updates and lifecycle management. Scale is evident in public reporting: according to the U.S. Centers for Disease Control and Prevention (CDC), the country administered hundreds of millions of COVID19 vaccine doses cumulatively, including ongoing booster campaigns tracked through 2024. Government funding and contracting significantly reduced development and scale-up risks for industry players. The U.S. Department of Health and Human Services (HHS) reported that initiatives during 2020–2021 included multibilliondollar financial support and advance purchase commitments for COVID19 vaccines, which expanded domestic manufacturing capacity and secured critical RNA production inputs. Regulatory support further reinforced the market: according to the U.S. Food and Drug Administration (FDA), multiple authorizations, approvals, and strain/formulation updates were executed for COVID19 vaccines between 2020 and 2023, establishing a proven operational pathway for ongoing platform updates and repeat purchasing.
RNA-Based Therapeutics and Vaccines Market- Competitive Landscape:
The competitive landscape of the RNA-based therapeutics and vaccines market features a mix of platform-focused innovators, RNA modality specialists, and large pharmaceutical companies expanding capabilities through internal development and strategic partnerships. Moderna, Inc. and BioNTech SE are recognized for their robust mRNA platform expertise and large-scale vaccine manufacturing experience, while Pfizer Inc. is notable for its global commercial scale and distribution network established during pandemic deployment. Alnylam Pharmaceuticals, Inc. is known for clinically validated siRNA programs and proven liver-targeted delivery, and Ionis Pharmaceuticals, Inc. is distinguished for long-standing antisense oligonucleotide development and extensive collaboration activity. Large pharma companies, including GSK plc, Sanofi, Novartis AG, Roche Holding AG, and Merck & Co., Inc., leverage global development infrastructure, regulatory capabilities, and manufacturing networks, often competing through partnerships,
Recent Developments:
- February 2024: The Coalition for Epidemic Preparedness Innovations (CEPI) awarded US$5 million to Ethris, a clinical-stage biotech, to advance proof-of-concept research on spray-dried RNA vaccines. These vaccines are designed to remain stable at room temperature, support mucosal (nasal) delivery, and simplify distribution in low-resource settings while potentially enhancing mucosal immunity.
- August 2025: Massachusetts Institute of Technology (MIT) introduced an AI-driven platform for optimizing lipid nanoparticles (LNPs) called COMET, trained on over 3,000 LNP formulations from the LANCE dataset. Laboratory validation demonstrated improved delivery efficiency for RNA therapeutics, accelerating development timelines, with support from the U.S. Advanced Research Projects Agency for Health (ARPA-H).
- March 2025: Singapore’s National Research Foundation (NRF) launched the National Initiative for RNA Biology and Its Applications (NIRBA) with S$130 million over seven years. This initiative brings together institutions such as NUS, NTU Singapore, A*STAR, and Duke-NUS to strengthen RNA research, translational capabilities, and collaborative infrastructure for vaccines and therapeutics.
- August 2025: The UK Government committed £29.6 million to establish the UK RNA Biofoundry at CPI’s RNA Centre of Excellence in Darlington. This facility aims to reduce the cost and complexity of producing clinical-grade RNA at early-stage scale, accelerate clinical development, and enhance national preparedness by maintaining capacity for rapid vaccine production if needed.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Acuitas Therapeutics, Inc.
- Alnylam Pharmaceuticals, Inc.
- Arcturus Therapeutics Holdings Inc.
- Arrowhead Pharmaceuticals, Inc.
- AstraZeneca PLC
- Beam Therapeutics Inc.
- BioNTech SE
- CureVac N.V.
- GSK plc
- Ionis Pharmaceuticals, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Moderna, Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Roche Holding AG
- Sanofi
- Sarepta Therapeutics, Inc.
- Translate Bio, Inc.
- Others
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032
- RNA Therapeutics
- RNA Vaccines
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET, BY RNA TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032
- mRNA
- siRNA
- Antisense Oligonucleotides (ASO)
- microRNA (miRNA)
- Other RNA Technologies
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Infectious Diseases
- Oncology
- Genetic/Rare Diseases
- Cardiovascular Diseases
- Other Indications
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals & Clinics
- Research Institutes & Academic Centers
- Pharmaceutical & Biotechnology Companies
- Contract Research/Manufacturing Organizations (CROs/CMOs)
- Other End Users
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
TABLE OF CONTENT
1. RNA-Based Therapeutics and Vaccines Market Overview
1.1. Study Scope
1.2. Market Estimation Years
2. Executive Summary
2.1. Market Snippet
2.1.1. RNA-Based Therapeutics and Vaccines Market Snippet by Product Type
2.1.2. RNA-Based Therapeutics and Vaccines Market Snippet by RNA Technology
2.1.3. RNA-Based Therapeutics and Vaccines Market Snippet by Indication
2.1.4. RNA-Based Therapeutics and Vaccines Market Snippet by End User
2.1.5. RNA-Based Therapeutics and Vaccines Market Snippet by Country
2.1.6. RNA-Based Therapeutics and Vaccines Market Snippet by Region
2.2. Competitive Insights
3. RNA-Based Therapeutics and Vaccines Key Market Trends
3.1. RNA-Based Therapeutics and Vaccines Market Drivers
3.1.1. Impact Analysis of Market Drivers
3.2. RNA-Based Therapeutics and Vaccines Market Restraints
3.2.1. Impact Analysis of Market Restraints
3.3. RNA-Based Therapeutics and Vaccines Market Opportunities
3.4. RNA-Based Therapeutics and Vaccines Market Future Trends
4. RNA-Based Therapeutics and Vaccines Industry Study
4.1. PEST Analysis
4.2. Porter’s Five Forces Analysis
4.3. Growth Prospect Mapping
4.4. Regulatory Framework Analysis
5. RNA-Based Therapeutics and Vaccines Market: Impact of Escalating Geopolitical Tensions
5.1. Impact of COVID-19 Pandemic
5.2. Impact of Russia-Ukraine War
5.3. Impact of Middle East Conflicts
6. RNA-Based Therapeutics and Vaccines Market Landscape
6.1. RNA-Based Therapeutics and Vaccines Market Share Analysis, 2024
6.2. Breakdown Data, by Key Manufacturer
6.2.1. Established Players’ Analysis
6.2.2. Emerging Players’ Analysis
7. RNA-Based Therapeutics and Vaccines Market – By Product Type
7.1. Overview
7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
7.1.2. RNA Therapeutics
7.1.3. RNA Vaccines
8. RNA-Based Therapeutics and Vaccines Market – By RNA Technology
8.1. Overview
8.1.1. Segment Share Analysis, By RNA Technology, 2024 & 2032 (%)
8.1.2. mRNA
8.1.3. siRNA
8.1.4. Antisense Oligonucleotides (ASO)
8.1.5. microRNA (miRNA)
8.1.6. Other RNA Technologies
9. RNA-Based Therapeutics and Vaccines Market – By Indication
9.1. Overview
9.1.1. Segment Share Analysis, By Indication, 2024 & 2032 (%)
9.1.2. Infectious Diseases
9.1.3. Oncology
9.1.4. Genetic/Rare Diseases
9.1.5. Cardiovascular Diseases
9.1.6. Other Indications
10. RNA-Based Therapeutics and Vaccines Market – By End User
10.1. Overview
10.1.1. Segment Share Analysis, By RNA Technology, 2024 & 2032 (%)
10.1.2. Hospitals & Clinics
10.1.3. Research Institutes & Academic Centers
10.1.4. Pharmaceutical & Biotechnology Companies
10.1.5. Contract Research/Manufacturing Organizations (CROs/CMOs)
10.1.6. Other End Users
11. RNA-Based Therapeutics and Vaccines Market– By Geography
11.1. Introduction
11.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
11.2. North America
11.2.1. Overview
11.2.2. RNA-Based Therapeutics and Vaccines Key Manufacturers in North America
11.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.2.5. North America Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.2.6. North America Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.7. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.2.8. U.S.
11.2.8.1. Overview
11.2.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.8.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.2.8.4. U.S. Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.2.8.5. U.S. Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.8.6. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.2.9. Canada
11.2.9.1. Overview
11.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.2.9.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.2.9.4. Canada Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.2.9.5. Canada Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.2.9.6. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3. Europe
11.3.1. Overview
11.3.2. RNA-Based Therapeutics and Vaccines Key Manufacturers in Europe
11.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.5. Europe Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.3.6. Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.7. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.8. Germany
11.3.8.1. Overview
11.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.8.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.8.4. Germany Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.3.8.5. Germany Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.8.6. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.9. UK
11.3.9.1. Overview
11.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.9.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.9.4. UK Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.3.9.5. UK Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.9.6. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.10. France
11.3.10.1. Overview
11.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.10.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.10.4. France Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.3.10.5. France Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.10.6. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.11. Italy
11.3.11.1. Overview
11.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.11.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.11.4. Italy Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.3.11.5. Italy Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.11.6. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.12. Spain
11.3.12.1. Overview
11.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.12.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.12.4. Spain Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.3.12.5. Spain Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.12.6. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.13. The Netherlands
11.3.13.1. Overview
11.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.13.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.13.4. The Netherlands Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.3.13.5. The Netherlands Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.13.6. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.14. Sweden
11.3.14.1. Overview
11.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.14.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.14.4. Sweden Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.3.14.5. Sweden Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.14.6. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.15. Russia
11.3.15.1. Overview
11.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.15.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.15.4. Russia Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.3.15.5. Russia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.15.6. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.16. Poland
11.3.16.1. Overview
11.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.16.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.16.4. Poland Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.3.16.5. Poland Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.16.6. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.3.17. Rest of Europe
11.3.17.1. Overview
11.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.3.17.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.3.17.4. Rest of the Europe Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.3.17.5. Rest of the Europe Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.3.17.6. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4. Asia Pacific (APAC)
11.4.1. Overview
11.4.2. RNA-Based Therapeutics and Vaccines Key Manufacturers in Asia Pacific
11.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.5. APAC Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.4.6. APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.7. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.8. China
11.4.8.1. Overview
11.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.8.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.8.4. China Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.4.8.5. China Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.8.6. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.9. India
11.4.9.1. Overview
11.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.9.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.9.4. India Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.4.9.5. India Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.9.6. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.10. Japan
11.4.10.1. Overview
11.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.10.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.10.4. Japan Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.4.10.5. Japan Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.10.6. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.11. South Korea
11.4.11.1. Overview
11.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.11.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.11.4. South Korea Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.4.11.5. South Korea Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.11.6. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.12. Australia
11.4.12.1. Overview
11.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.12.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.12.4. Australia Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.4.12.5. Australia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.12.6. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.13. Indonesia
11.4.13.1. Overview
11.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.13.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.13.4. Indonesia Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.4.13.5. Indonesia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.13.6. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.14. Thailand
11.4.14.1. Overview
11.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.14.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.14.4. Thailand Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.4.14.5. Thailand Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.14.6. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.15. Philippines
11.4.15.1. Overview
11.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.15.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.15.4. Philippines Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.4.15.5. Philippines Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.15.6. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.4.16. Rest of APAC
11.4.16.1. Overview
11.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.4.16.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.4.16.4. Rest of APAC Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.4.16.5. Rest of APAC Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.4.16.6. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5. Latin America (LATAM)
11.5.1. Overview
11.5.2. RNA-Based Therapeutics and Vaccines Key Manufacturers in Latin America
11.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.5. LATAM Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.5.6. LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.7. LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.8. Brazil
11.5.8.1. Overview
11.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.8.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.8.4. Brazil Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.5.8.5. Brazil Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.8.6. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.9. Mexico
11.5.9.1. Overview
11.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.9.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.9.4. Mexico Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.5.9.5. Mexico Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.9.6. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.10. Argentina
11.5.10.1. Overview
11.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.10.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.10.4. Argentina Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.5.10.5. Argentina Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.10.6. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.11. Colombia
11.5.11.1. Overview
11.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.11.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.11.4. Colombia Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.5.11.5. Colombia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.11.6. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.5.12. Rest of LATAM
11.5.12.1. Overview
11.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.5.12.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.5.12.4. Rest of LATAM Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.5.12.5. Rest of LATAM Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.5.12.6. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6. Middle East and Africa (MEA)
11.6.1. Overview
11.6.2. RNA-Based Therapeutics and Vaccines Key Manufacturers in Middle East and Africa
11.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
11.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.5. MEA Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.6.6. MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.7. MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.8. Saudi Arabia
11.6.8.1. Overview
11.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.8.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.8.4. Saudi Arabia Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.6.8.5. Saudi Arabia Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.8.6. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.9. United Arab Emirates
11.6.9.1. Overview
11.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.9.3. United Arab Emirates Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.9.4. United Arab Emirates Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.6.9.5. United Arab Emirates Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.9.6. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.10. Israel
11.6.10.1. Overview
11.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.10.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.10.4. Israel Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.6.10.5. Israel Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.10.6. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.11. Turkey
11.6.11.1. Overview
11.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.11.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.11.4. Turkey Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.6.11.5. Turkey Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.11.6. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.12. Algeria
11.6.12.1. Overview
11.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.12.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.12.4. Algeria Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.6.12.5. Algeria Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.12.6. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.13. Egypt
11.6.13.1. Overview
11.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.13.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.13.4. Egypt Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.6.13.5. Egypt Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.13.6. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
11.6.14. Rest of MEA
11.6.14.1. Overview
11.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
11.6.14.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
11.6.14.4. Rest of MEA Market Size and Forecast, By RNA Technology, 2019 - 2032 (US$ Million)
11.6.14.5. Rest of MEA Market Size and Forecast, By Indication, 2019 - 2032 (US$ Million)
11.6.14.6. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
12. Key Vendor Analysis- RNA-Based Therapeutics and Vaccines Industry
12.1. Competitive Benchmarking
12.1.1. Competitive Dashboard
12.1.2. Competitive Positioning
12.2. Company Profiles
12.2.1. Acuitas Therapeutics, Inc.
12.2.2. Alnylam Pharmaceuticals, Inc.
12.2.3. Arcturus Therapeutics Holdings Inc.
12.2.4. Arrowhead Pharmaceuticals, Inc.
12.2.5. AstraZeneca PLC
12.2.6. Beam Therapeutics Inc.
12.2.7. BioNTech SE
12.2.8. CureVac N.V.
12.2.9. GSK plc
12.2.10. Ionis Pharmaceuticals, Inc.
12.2.11. Johnson & Johnson
12.2.12. Merck & Co., Inc.
12.2.13. Moderna, Inc.
12.2.14. Novartis AG
12.2.15. Pfizer Inc.
12.2.16. Regeneron Pharmaceuticals, Inc.
12.2.17. Roche Holding AG
12.2.18. Sanofi
12.2.19. Sarepta Therapeutics, Inc.
12.2.20. Translate Bio, Inc.
12.2.21. Others
13. 360 Degree AnalystView
14. Appendix
14.1. Research Methodology
14.2. References
14.3. Abbreviations
14.4. Disclaimer
14.5. Contact Us
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
- Acuitas Therapeutics, Inc.
- Alnylam Pharmaceuticals, Inc.
- Arcturus Therapeutics Holdings Inc.
- Arrowhead Pharmaceuticals, Inc.
- AstraZeneca PLC
- Beam Therapeutics Inc.
- BioNTech SE
- CureVac N.V.
- GSK plc
- Ionis Pharmaceuticals, Inc.
- Johnson & Johnson
- Merck & Co., Inc.
- Moderna, Inc.
- Novartis AG
- Pfizer Inc.
- Regeneron Pharmaceuticals, Inc.
- Roche Holding AG
- Sanofi
- Sarepta Therapeutics, Inc.
- Translate Bio, Inc.
- Others
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032
- RNA Therapeutics
- RNA Vaccines
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET, BY RNA TECHNOLOGY- MARKET ANALYSIS, 2019 - 2032
- mRNA
- siRNA
- Antisense Oligonucleotides (ASO)
- microRNA (miRNA)
- Other RNA Technologies
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET, BY INDICATION- MARKET ANALYSIS, 2019 - 2032
- Infectious Diseases
- Oncology
- Genetic/Rare Diseases
- Cardiovascular Diseases
- Other Indications
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032
- Hospitals & Clinics
- Research Institutes & Academic Centers
- Pharmaceutical & Biotechnology Companies
- Contract Research/Manufacturing Organizations (CROs/CMOs)
- Other End Users
GLOBAL RNA-BASED THERAPEUTICS AND VACCINES MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032
North America
- U.S.
- Canada
Europe
- Germany
- UK
- France
- Italy
- Spain
- The Netherlands
- Sweden
- Russia
- Poland
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- South Korea
- Australia
- Indonesia
- Thailand
- Philippines
- Rest of APAC
Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
The Middle East and Africa
- Saudi Arabia
- UAE
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA
Related Reports
Credibility and Certifications
Trusted Insights, Certified Excellence! Coherent Market Insights is a certified data advisory and business consulting firm recognized by global institutes.
ISO 9001:2015
ESOMAR Corporate
GDPR Compliance
D-U-N-S Registered
BBB Accreditation
MRS
